Evidence map›Paper›PMID 41816602›Full record

ArticleJournal of gastrointestinal oncology2026

ΔSII-based nomogram for prognosis prediction after radical resection for hepatocellular carcinoma.

Yang Zou, Min Jin, Ming Luo, Kai He

Abstract read
In one paragraph

Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Yang ZouDepartment of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Min JinDepartment of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Ming LuoDepartment of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Kai HeDepartment of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary liver cancer (PLC) ranks sixth in global incidence and third in cancer mortality. Chronic inflammation drives hepatocarcinogenesis via fibrosis. Despite curative resection, hepatocellular carcinoma (HCC) patients have high recurrence rates (50% at 3 years and 70% at 5 years). In addition to pathological factors [e.g., an alpha-fetoprotein (AFP) concentration >400 ng/L and vascular invasion], systemic immune inflammation influences the prognosis. The systemic immune-inflammation index (SII) has prognostic value, but the preoperative SII does not account for surgical impact. We propose a novel postoperative/preoperative SII ratio (ΔSII) to predict survival and recurrence, integrated into a ΔSII-based prognostic nomogram. Methods: We retrospectively analyzed 244 HCC patients undergoing radical resection, randomly divided into training (n=171) and validation (n=73) cohorts at a 7:3 ratio. The optimal ΔSII cutoff for overall survival (OS) was determined by receiver operating characteristic (ROC) curve analysis. Clinicopathologic associations were assessed with Chi-squared/Fisher tests. Variable selection involved univariable Cox, least absolute shrinkage and selection operator (LASSO), and Boruta algorithms; multivariable Cox models were used to construct OS/recurrence-free survival (RFS) nomograms. Performance was evaluated via time-dependent area under the curve (AUC), calibration curves, and decision curve analysis (DCA). Results: The ΔSII outperformed preoperative SII in predicting OS (AUC: 0.770 Conclusions: The ΔSII-based nomogram effectively predicts OS/RFS after resection, enabling individualized management for high-risk HCC patients.

Indexed as

hepatocellular carcinoma (HCC)nomogramprognosisrisk stratificationSystemic immune-inflammation index (SII)

Identifiers

PMID41816602
PMCPMC12972030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.